Please check your internet connection and try again.
# Arsil (Silymarin/Silybin)
## Overview
Arsil is a standardized extract of *Silybum marianum* (milk thistle), primarily containing the flavonolignan silybin. It is commonly utilized as a hepatoprotective agent and antioxidant. Note: Product standardization varies significantly by manufacturer; clinical efficacy remains controversial in Western medicine.
## Primary Indications
* Supportive treatment for chronic liver disease (cirrhosis, chronic hepatitis).
* Adjunctive therapy for toxic liver damage (e.g., *Amanita phalloides* mushroom poisoning).
## Adult Dosing
* **Chronic Liver Disease:** 140 mg to 280 mg of standardized Silymarin, administered orally 2–3 times daily.
* **Amanita phalloides poisoning:** Intravenous Silybin (Legalon SIL) 20–50 mg/kg/day, typically divided into 4 doses administered as a 1-hour infusion. **Note:** IV formulation is not available in all regions.
## Pediatric Dosing
* **Chronic Liver Disease:** No established standardized pediatric dose. Use is generally not recommended without specialist guidance.
* **Amanita phalloides poisoning:** 20–50 mg/kg/day IV (divided into 4 doses). Consult local pediatric toxicology or poison control protocols immediately.
## Dose Adjustments
* **Renal/Hepatic Impairment:** No specific manufacturer guidelines available. Due to potential biliary excretion, monitor closely in severe hepatic impairment.
## Contraindications
* Known hypersensitivity to *Asteraceae/Compositae* family plants (e.g., ragweed, chrysanthemums, marigolds).
* Hormone-sensitive conditions (e.g., breast, uterine, or ovarian cancer) due to potential weak estrogenic activity.
## Adverse Effects
* **Gastrointestinal:** Diarrhea (most common), abdominal bloating, dyspepsia, nausea.
* **Dermatological:** Pruritus, skin rash (rare).
* **Systemic:** Anaphylaxis (rare hypersensitivity reaction).
## Key Drug Interactions
* **CYP450 Substrates/Inhibitors:** Potential for mild inhibition of CYP2C9 and CYP3A4; use caution with narrow therapeutic index drugs (e.g., warfarin, phenytoin) and monitor international normalized ratio (INR) if co-administered.
* **Diabetes Medications:** May lower blood glucose levels; monitor patient for hypoglycemia when combined with insulin or oral hypoglycemics.
## Monitoring
* **Efficacy:** Liver function tests (ALT, AST, bilirubin) and clinical assessment of symptomatic resolution.
* **Safety:** Blood glucose levels (in diabetics) and signs of allergic reaction.
## Clinical Pearls
* **Regulatory Status:** Frequently marketed as a dietary supplement; "Arsil" may refer to various regional brands. Verify the specific silybin-to-silymarin content, as bioavailability is highly product-dependent.
* **Bioavailability:** Poor aqueous solubility limits oral absorption. Products complexed with phospholipids (e.g., silybin-phosphatidylcholine) generally demonstrate superior bioavailability.
* **Poisoning:** In *Amanita* poisoning, Silymarin should never replace urgent stabilization, gastric decontamination, or charcoal administration.
***
**Educational Disclaimer:** This information is for educational purposes only and does not constitute medical advice. Always verify current prescribing information, local clinical protocols, and pharmacy formulary guidelines before initiating therapy. Contact a poison control center immediately in the event of suspected toxin ingestion.
